ProQR Therapeutics (PRQR) Return on Capital Employed (2014 - 2026)
ProQR Therapeutics (PRQR) posted quarterly Return on Capital Employed of 65.33% for Q1 2026, down 3899.0% year-on-year from 1.72% in Q1 2025, and down 29.49% on a QoQ basis from 50.45% in Q4 2025.
ProQR Therapeutics (PRQR) Return on Capital Employed (2014 - 2026) Analysis & Trends
ProQR Therapeutics (PRQR) has reported Return on Capital Employed for 12 consecutive years, with 65.33% the latest figure, recorded in Q1 2026.
- Quarterly Return on Capital Employed fell 3899.0% year-over-year to 65.33% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 65.33% (down 3899.0% YoY) and the FY2025 annual result came in at 40.26%, down 1353.0% from the prior year.
- Return on Capital Employed retreated to 65.33% in Q1 2026 per PRQR's latest filing, from 50.45% in the prior quarter.
- Over the last five years, Return on Capital Employed for PRQR reached as high as 26.34% in Q1 2025 and fell as low as 65.33% in Q1 2026.
- A 5-year average of 39.98% and a median of 37.54% in 2025 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2022 — Return on Capital Employed tumbled 4101 bps — and 2023, when it soared 2459 bps.
- Year by year, Return on Capital Employed stood at 51.9% in 2022, then surged by 42 bps to 30.13% in 2023, then decreased by 3 bps to 30.94% in 2024, then slumped by 63 bps to 50.45% in 2025, then declined by 29 bps to 65.33% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 65.33%, 50.45%, and 45.43% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | ProQR Therapeutics | 219.53 Mn | 175.72 Mn | - | -65.33% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -65.33% |
| Dec 31, 2025 | -50.45% |
| Sep 30, 2025 | -45.43% |
| Jun 30, 2025 | -37.54% |
| Mar 31, 2025 | -26.34% |
| Dec 31, 2024 | -30.94% |
| Sep 30, 2024 | -36.61% |
| Jun 30, 2024 | -30.27% |
| Mar 31, 2024 | -31.67% |
| Dec 31, 2023 | -30.13% |
| Sep 30, 2023 | -32.15% |
| Jun 30, 2023 | -38.83% |
| Mar 31, 2023 | -38.98% |
| Dec 31, 2022 | -51.90% |
| Sep 30, 2022 | -56.74% |
| Jun 30, 2022 | -41.12% |
| Mar 31, 2022 | -35.26% |
| Dec 31, 2021 | -32.71% |
| Sep 30, 2021 | -35.75% |
| Jun 30, 2021 | -0.10% |